JP2022551105A5 - - Google Patents
Info
- Publication number
- JP2022551105A5 JP2022551105A5 JP2022520638A JP2022520638A JP2022551105A5 JP 2022551105 A5 JP2022551105 A5 JP 2022551105A5 JP 2022520638 A JP2022520638 A JP 2022520638A JP 2022520638 A JP2022520638 A JP 2022520638A JP 2022551105 A5 JP2022551105 A5 JP 2022551105A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- eosinophilic
- therapeutically effective
- effective dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025135336A JP2025169361A (ja) | 2019-10-04 | 2025-08-15 | アバプリチニブでの好酸球性障害の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910931P | 2019-10-04 | 2019-10-04 | |
| US62/910,931 | 2019-10-04 | ||
| PCT/US2020/054221 WO2021067917A1 (en) | 2019-10-04 | 2020-10-05 | Treatment of eosinophilic disorders with avapritinib |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025135336A Division JP2025169361A (ja) | 2019-10-04 | 2025-08-15 | アバプリチニブでの好酸球性障害の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551105A JP2022551105A (ja) | 2022-12-07 |
| JP2022551105A5 true JP2022551105A5 (cg-RX-API-DMAC7.html) | 2023-10-13 |
Family
ID=73030210
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520638A Pending JP2022551105A (ja) | 2019-10-04 | 2020-10-05 | アバプリチニブでの好酸球性障害の治療 |
| JP2025135336A Pending JP2025169361A (ja) | 2019-10-04 | 2025-08-15 | アバプリチニブでの好酸球性障害の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025135336A Pending JP2025169361A (ja) | 2019-10-04 | 2025-08-15 | アバプリチニブでの好酸球性障害の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240075041A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4041244B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022551105A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114746096A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202126306A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021067917A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2593319T3 (es) * | 2005-05-02 | 2016-12-07 | Novartis Ag | Derivados de pirimidilaminobenzamida para síndrome hipereosinofílico |
| JP2009515978A (ja) * | 2005-11-14 | 2009-04-16 | バイエル ヘルスケア エルエルシー | Kit阻害剤に対する獲得耐性を伴う癌の治療 |
| ES2429107T3 (es) * | 2007-01-19 | 2013-11-13 | Bayer Healthcare Llc | Tratamiento de cánceres con una resistencia adquirida a los agentes inhibidores de KIT |
| ES2573831T3 (es) * | 2011-07-27 | 2016-06-10 | Ab Science | Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit) |
| EP2768480A1 (en) * | 2011-10-21 | 2014-08-27 | Rigel Pharmaceuticals, Inc. | Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4]oxazin-3-one) -6-yl]-5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine |
| KR101652229B1 (ko) * | 2012-06-07 | 2016-08-30 | 데시페라 파마슈티칼스, 엘엘씨. | 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물 |
| MX365614B (es) * | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
| CN109970745B (zh) * | 2018-04-16 | 2020-12-08 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡咯并三嗪类化合物及其药物组合物及其用途 |
-
2020
- 2020-10-05 CN CN202080081643.7A patent/CN114746096A/zh active Pending
- 2020-10-05 WO PCT/US2020/054221 patent/WO2021067917A1/en not_active Ceased
- 2020-10-05 TW TW109134501A patent/TW202126306A/zh unknown
- 2020-10-05 EP EP20797912.1A patent/EP4041244B1/en active Active
- 2020-10-05 JP JP2022520638A patent/JP2022551105A/ja active Pending
- 2020-10-05 US US17/766,200 patent/US20240075041A1/en active Pending
-
2025
- 2025-08-15 JP JP2025135336A patent/JP2025169361A/ja active Pending